Obesity Medicine

Study participants randomized to placebo for 1 year after 36 weeks on tirzepatide had mean weight regain of 14% vs augmented loss among those who continued on the medication.

While incretin-based antiobesity medications are the optimal treatment for some, there are other less costly approaches that can support weight loss success, this author says.

The dual GIP/GLP-1 mimetic is available by prescription for adults with obesity or overweight with comorbidities and Lilly is offering a savings card program.

The 5 leading advocacy groups said the safety of people with obesity is at risk and called on the FDA to change clinical trial inclusion requirements and expedite labeling changes.

Your daily dose of the clinical news you may have missed.

An obesity specialist discusses the importance of using a weight-first approach when educating patients about obesity's role in the development and worsening of hypertension.

"Primary care physicians... really are like the quarterbacks" for initiating multidisciplinary care for CKM syndrome, says Dr Chiadi Ndumele.

Absolute risk assessment for CVD remains the corner-stone of clinical primary prevention efforts. The new AHA prediction models expand that foundation.

Your daily dose of the clinical news you may have missed.

Patients with obesity and hypertension need to be aggressively treated in order to decrease their risk of cardiovascular complications, says Dr Jonathan Parker, President of the Alabama Obesity Society.

Managing cardiovascular-kidney-metabolic syndrome on a population-wide basis requires that social determinants of health be treated like any other risk factor, according to Ndumele.

From highest percentage of children with obesity to lowest percentage of adults with hypercholesterolemia, see how obesity hits home in our new slideshow.

Dr Chiadi Ndumele explains the need for the more comprehensive and also nuanced qualitative approach to estimating long-term CVD risk.

Your daily dose of the clinical news you may have missed.

Which hypertension treatment options should be used as first-line therapy in patients with obesity? A clinician's answer and explanation, here.

AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.

TLM 2023: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide 8 mg and 12 mg resolved steatosis in >85% of subjects.

The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.

President of the Alabama Obesity Society, Dr Jonathan Parker, discusses obesity as a risk factor for hypertension.

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

Your daily dose of the clinical news you may have missed.

Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The 2 highest doses of tirzepatide were ranked most likely to be effective for weight management in persons without diabetes, followed by semaglutide 2.4 mg.

In postmenopausal women with HR+ breast cancer who had obesity, recurrence of breast cancer while on aromatase inhibitor therapy was 18%, report investigators.

President of the Alabama Obesity Society, Dr Jonathan Parker, provides an in-depth overview of the association between obesity and hypertension.

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.

A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.

Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.